This study evaluated 41 patients with MET-high, KRAS wild-type mCRC, who were treated with ≥1 prior systemic therapy, with at least SD on the last treatment regimen containing cetuximab or panitumumab and tumor progression within 3 months before enrollment. The gene discussed is KRAS; the disease is neoplasm.